Bausch & Lomb Corp (BLCO) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Bausch & Lomb Corp (BLCO) stock forecast summary
On Oct. 16, 2026, BLCO is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
Bausch & Lomb Corp is a mid-cap company with a market capitalization of $5.89B. It ranks number 3 by market capitalization among the 8 Ophthalmic Goods issuers in our coverage with a current forecast.
For BLCO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 33.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 28.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BLCO included.
Follow BLCO freeBLCO price chart and AI forecast
How BLCO ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Bausch & Lomb Corp (BLCO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Ophthalmic Goods peers listed below that report each metric.
Valuation & Market
| Metric | BLCO | Rank |
|---|---|---|
| Market Cap | $5.89B | 3/8 |
| P/B Ratio | 0.92x | 6/7 |
| EPS | $-0.88 | – |
| Book Value/Share | $17.85 | – |
| Revenue/Share | $14.91 | – |
| FCF/Share | $0.38 | – |
Profitability & Margins
| Metric | BLCO | Rank |
|---|---|---|
| ROE | -2.7% | – |
| ROA | -1.2% | – |
| ROIC | 2.7% | 4/5 |
| Operating Margin | 6.1% | 2/6 |
| Net Margin | -3.2% | – |
| EBT Margin | -1.2% | 5/6 |
| Tax Rate | -150.8% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | BLCO | Rank |
|---|---|---|
| Current Ratio | 1.55x | 5/7 |
| Quick Ratio | 1.02x | 5/7 |
| D/E Ratio | 1.16x | 2/8 |
| Financial Leverage | 2.17x | 2/6 |
| Interest Coverage | 0.9x | 5/6 |
| Working Capital | $1.03B | 1/7 |
Cash Flow
| Metric | BLCO | Rank |
|---|---|---|
| Operating Cash Flow | $458M | 2/7 |
| Free Cash Flow | $137M | 2/6 |
| Capital Spending | -$321M | 5/6 |
| OCF Growth YoY | 146.2% | – |
| FCF/Sales | 2.6% | 2/6 |
| CapEx/Sales | 6.0% | 3/6 |
Operational Efficiency
| Metric | BLCO | Rank |
|---|---|---|
| Asset Turnover | 0.38x | 4/6 |
| Receivables Turnover | 4.6x | 6/7 |
| Fixed Assets Turnover | 3.0x | 6/7 |
| Days Sales Outstanding | 80 days | 2/7 |
Income Statement
| Metric | BLCO | Rank |
|---|---|---|
| Total Revenue | $5.32B | 2/8 |
| Operating Income | $323M | 2/6 |
| Net Income | -$171M | – |
| R&D Expense | $404M | 1/5 |
| SG&A Expense | $2.22B | 2/8 |
Dividend & Shareholder Information
| Metric | BLCO | Rank |
|---|---|---|
| Shares Outstanding | 357M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $2.92B | 21.1% of assets |
| Cash & Short-term Investments | $367M | 2.6% of assets |
| Accounts Receivable | $1.16B | 8.4% of assets |
| Inventory | $999M | 7.2% of assets |
| Total Liabilities | $7.42B | 53.5% of assets |
| Short-term Debt | $1.46B | 10.6% of assets |
BLCO quarterly financials and insider trading
Bausch & Lomb Corp (BLCO) industry peers
Companies classified under the same SEC industry code as Bausch & Lomb Corp (Ophthalmic Goods): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| BLCO Bausch & Lomb Corp | ▶ | $5.89B |
| ALC Alcon Inc | ▼ | $32.26B |
| COO Cooper Companies, Inc. | ▼ | $11.02B |
| WRBY Warby Parker Inc. | ▲ | $2.89B |
| EYE National Vision Holdings, Inc. | ▶ | $1.38B |
| STAA Staar Surgical Co | ▶ | $1.07B |
| RXST Rxsight, Inc. | ▲ | $188M |
| LUCY Innovative Eyewear Inc | ▶ | $7M |
Where BLCO sits on the market map
Bausch & Lomb Corp (BLCO) stock news
Loading...
Bausch & Lomb Corp (BLCO) stock forecast FAQ
What is the Bausch & Lomb Corp (BLCO) stock forecast?
On Oct. 16, 2026, BLCO is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Bausch & Lomb Corp stock predictions?
For BLCO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 33.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 28.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Bausch & Lomb Corp forecasts updated?
Bausch & Lomb Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Bausch & Lomb Corp's industry peers?
8 issuers in our coverage, BLCO included, share the SEC industry code Ophthalmic Goods. The largest are: Alcon Inc (ALC), Cooper Companies, Inc. (COO), Warby Parker Inc. (WRBY), National Vision Holdings, Inc. (EYE), Staar Surgical Co (STAA), Rxsight, Inc. (RXST).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.